+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Cancer Diagnostics Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • PDF Icon

    Report

  • 189 Pages
  • February 2024
  • Region: Global
  • Infogence Global Research
  • ID: 5942433
The Global Cancer Diagnostics Market is estimated to be USD 178.02 Bn in 2022 and is expected to reach USD 270.9 Bn by 2027, growing at a CAGR of 8.76%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the Global Cancer Diagnostics Market stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentations

  • The Global Cancer Diagnostics Market is segmented based on Diagnostic Type, Indication, Product, End User, and Geography.
  • By Diagnostic Type, the market is classified into Biopsy and Cytology Test, Diagnostic Imaging Test and Tumor Biomarkers.
  • By Indication, the market is classified into Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, and Skin Cancer.
  • By Product, the market is classified into Consumables and Instruments.
  • By End User, the market is classified into Hospitals and Diagnostics Laboratories.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Abbott Laboratories, Agilent Technologies, Inc., Becton Dickinson & Company, Bio-Rad Laboratories, Inc., bioMérieux SA, Cancer Diagnostics, Inc., etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Cancer Diagnostics Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The publisher analyses the Global Cancer Diagnostics Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Cancer Diagnostics Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations and Outlook
4 Market Dynamics
4.1 Drivers
4.1.1 Rising Aging Population and Rising Prevalence of Cancer
4.1.2 Increasing Government Initiatives for Funding and Awareness about Cancer
4.1.3 Evolution of Artificial Intelligence and the Imminent Health
4.2 Restraints
4.2.1 High Cost of Diagnostic Imaging Systems
4.2.2 High Capital Investments and Low Cost-benefit Ratio for Biomarkers
4.3 Opportunities
4.3.1 Emerging Nanotechnology in Cancer Diagnosis
4.3.2 Rise in the Amalgamation Strategies by the Market Players in the Cancer Diagnostics
4.3.3 Growing Focus on Personalized Medicine
4.4 Challenges
4.4.1 Lack of Skilled Professionals
4.4.2 Inadequate Infrastructure and Low Awareness in Middle- and Low-income Countries
4.4.3 Radiation Risk from Medical Imaging for Cancer
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Cancer Diagnostics Market, By Diagnostic Type
6.1 Introduction
6.2 Biopsy and Cytology Test
6.3 Diagnostic Imaging Test
6.4 Tumor Biomarkers
7 Global Cancer Diagnostics Market, By Indication
7.1 Introduction
7.2 Blood Cancer
7.3 Breast Cancer
7.4 Cervical Cancer
7.5 Colorectal Cancer
7.6 Kidney Cancer
7.7 Liver Cancer
7.8 Lung Cancer
7.9 Ovarian Cancer
7.10 Pancreatic Cancer
7.11 Prostate Cancer
7.12 Skin Cancer
8 Global Cancer Diagnostics Market, By Product
8.1 Introduction
8.2 Consumables
8.2.1 Antibodies
8.2.2 Kits & Reagents
8.2.3 Probes
8.3 Instruments
8.3.1 Pathology-based Instruments
8.3.2 Imaging Instruments
8.3.3 Biopsy Instruments
9 Global Cancer Diagnostics Market, By End User
9.1 Introduction
9.2 Hospitals
9.3 Diagnostic Laboratories
10 Americas’ Cancer Diagnostics Market
10.1 Introduction
10.2 Argentina
10.3 Brazil
10.4 Canada
10.5 Chile
10.6 Colombia
10.7 Mexico
10.8 Peru
10.9 United States
10.10 Rest of Americas
11 Europe’s Cancer Diagnostics Market
11.1 Introduction
11.2 Austria
11.3 Belgium
11.4 Denmark
11.5 Finland
11.6 France
11.7 Germany
11.8 Italy
11.9 Netherlands
11.10 Norway
11.11 Poland
11.12 Russia
11.13 Spain
11.14 Sweden
11.15 Switzerland
11.16 United Kingdom
11.17 Rest of Europe
12 Middle East and Africa’s Cancer Diagnostics Market
12.1 Introduction
12.2 Egypt
12.3 Israel
12.4 Qatar
12.5 Saudi Arabia
12.6 South Africa
12.7 United Arab Emirates
12.8 Rest of MEA
13 APAC’s Cancer Diagnostics Market
13.1 Introduction
13.2 Australia
13.3 Bangladesh
13.4 China
13.5 India
13.6 Indonesia
13.7 Japan
13.8 Malaysia
13.9 Philippines
13.10 Singapore
13.11 South Korea
13.12 Sri Lanka
13.13 Thailand
13.14 Taiwan
13.15 Rest of Asia-Pacific
14 Competitive Landscape
14.1 Competitive Quadrant
14.2 Market Share Analysis
14.3 Strategic Initiatives
14.3.1 M&A and Investments
14.3.2 Partnerships and Collaborations
14.3.3 Product Developments and Improvements
15 Company Profiles
15.1 Abbott Laboratories
15.2 Agilent Technologies, Inc.
15.3 Becton Dickinson & Company
15.4 Bio-Rad Laboratories, Inc.
15.5 bioMérieux SA
15.6 Cancer Diagnostics, Inc.
15.7 DiaSorin S.p.A
15.8 F. Hoffmann-La Roche, Ltd.
15.9 GlaxoSmithKline, PLC
15.10 GE Healthcare
15.11 Hologic, Inc.
15.12 Illumina, Inc.
15.13 Merck KGaA
15.14 Novartis Ag
15.15 Pfizer, Inc.
15.16 Philips Healthcare
15.17 Qiagen NV
15.18 Quest Diagnostics, Inc.
15.19 Siemens Healthcare GmbH
15.20 Thermo Fisher Scientific, Inc.
16 Appendix
16.1 Questionnaire

Companies Mentioned

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton Dickinson & Company
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Cancer Diagnostics, Inc.
  • DiaSorin S.p.A
  • F. Hoffmann-La Roche, Ltd.
  • GlaxoSmithKline, PLC
  • GE Healthcare
  • Hologic, Inc.
  • Illumina, Inc.
  • Merck KGaA
  • Novartis Ag
  • Pfizer, Inc.
  • Philips Healthcare
  • Qiagen NV
  • Quest Diagnostics, Inc.
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific, Inc.

Table Information